Invitation to Conference Call Regarding Promore Pharma's Interim Report for the First Quarter 2022

ACCESS Newswire
13 May 2022, 14:31 GMT+10

STOCKHOLM, SWEDEN / ACCESSWIRE / May 13, 2022 / Promore Pharma (STO:PROMO)(FRA:8T0)

STOCKHOLM, 13 May 2022 - Promore Pharma AB (publ) publishes its interim report for the first quarter 2022 on 17 May 2022.

The same day the company will host a webcast telephone conference at 16.00 CET, with President and CEO Jonas Ekblom and CFO Erik Magnusson, where an update for the quarter and upcoming activities. After the presentation there will be a Q&A session. The conference call will be held in English and can be accessed via computer, tablet, or telephone.

The number of attendees is limited, please register for the conference in advance on the following link:

https://attendee.gotowebinar.com/register/4045498425908535564

The conference call will be recorded and made available on the company´s website after the call, and on Västra Hamnen Corporate Finance Youtube channel.

About Promore Pharma

Promore Pharma is a biopharmaceutical company that develops pharmaceutical product candidates for bioactive wound care. Today, the company has two drug candidates in late clinical development stages, that are based on endogenous peptides, and thus have a strong safety profile. These two products are intended for treatment of chronic wounds, and prevention of scarring on the skin and other tissues. The company is listed on the Nasdaq First North Growth Market.

For additional information, please contact

Jonas Ekblom, CEO
Phone: [+46] 736 777 540
E-mail: [email protected]

Erik Magnusson, CFO
Phone: [+46] 708 565 245
E-mail: [email protected]

Promore Pharmas Certified Adviser is Erik Penser Bank
Tel: [+46] 8-463 83 00
E-mail: [email protected]

Attachments

Invitation to Conference Call regarding Promore Pharma's Interim Report for the First Quarter 2022

SOURCE: Promore Pharma

View source version on accesswire.com:
https://www.accesswire.com/701250/Invitation-to-Conference-Call-Regarding-Promore-Pharmas-Interim-Report-for-the-First-Quarter-2022

Watch latest videos

News RELEASES

Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Pennsylvania Sun.

More Information

null in null

Business

Section

Wall Street has relapse Wednesday, after Tuesday's heady gains

U.S. stocks slide as 30-year bond yields top 5 percent

NEW YORK, New York - U.S. stocks were weaker Wednesday, following Tuesday's heady gains when the Dow Jones jumped 741 points. Bond...

China’s GAC launches in Brazil as EV demand accelerates

China's GAC enters Brazil EV market, plans factory by 2026

SAO PAULO, Brazil: Amid a surge in electric vehicle (EV) adoption and growing competition in Brazil, Chinese automaker GAC has officially...

McDonald’s to shut down CosMc’s drink spinoff after short run

McDonald's to close standalone beverage concept

CHICAGO, Illinois: McDonald's is closing its experimental beverage spinoff, CosMc's, less than two years after launching the standalone...

China’s Lenovo profit plunges 64%, misses estimates sharply

China's Lenovo posts quarterly profit, short of estimates, shares slip

BEIJING, China: China's Lenovo reported a steep 64 percent drop in fourth-quarter profit, falling significantly short of analyst expectations...

Economic data gives welcome relief to Wall Street

Dow Jones soars 741 points on robust consumer confidence

NEW YORK, New York - Strong economic data jump-started U.S. stocks and the dollar Tuesday, a welcome reprieve after weeks of pressure...

PepsiCo cleared in FTC case over Walmart discounts

FTC drops price bias lawsuit against PepsiCo

NEW YORK CITY, New York: This week, the U.S. Federal Trade Commission (FTC) dropped its lawsuit against PepsiCo, which had accused...

Business

Section